300267 尔康制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.325-8.956-8.044-3.9510.928
总资产报酬率 ROA (%)0.267-7.550-6.993-3.4460.814
投入资产回报率 ROIC (%)0.275-7.798-7.235-3.6060.856

边际利润分析
销售毛利率 (%)28.42626.44427.52320.42422.220
营业利润率 (%)4.147-31.313-32.521-11.5930.737
息税前利润/营业总收入 (%)3.877-31.339-34.032-11.1511.634
净利润/营业总收入 (%)3.812-34.253-34.453-12.4421.982

收益指标分析
经营活动净收益/利润总额(%)59.468-0.37519.10756.875-66.062
价值变动净收益/利润总额(%)2.7405.87314.2774.561108.424
营业外收支净额/利润总额(%)-0.2050.7564.511-3.91720.596

偿债能力分析
流动比率 (X)2.0932.2282.4342.8692.883
速动比率 (X)1.5221.5901.5831.7231.750
资产负债率 (%)20.16718.24715.33812.21113.740
带息债务/全部投入资本 (%)14.91512.27510.0437.0757.715
股东权益/带息债务 (%)558.890700.051877.5751,295.7901,177.652
股东权益/负债合计 (%)402.148454.840557.642722.818627.794
利息保障倍数 (X)-14.803-147.599-1,336.839-2,082.7662.314

营运能力分析
应收账款周转天数 (天)45.51334.61433.53824.51530.811
存货周转天数 (天)263.273233.588281.647191.927190.048